


QUT partners with Omico to pave way for precision cancer care in Australia

22 April 2024 | News

To provide free access to personalised tumour analyses for 1600 Queensland cancer patients over the next 18 months



Australian Translational Genomics Centre (ATGC) at Queensland University of Technology (QUT) will help link Queensland patients with clinical trials to evaluate treatments to improve outcomes for people with cancer, owing to a new collaboration with non-profit research organisation Omico and the ProSPeCT programme.

The initiative will provide free access to personalised tumour analyses for 1600 Queensland cancer patients over the next 18 months and identify potential matches to new treatment trials.

The ProSPeCT program (short for Precision Oncology Screening Platform enabling Clinical Trials Australia) is run by Omico and has a \$185 million public-private funding commitment, with contributions from the Australian Government, NSW Government and industry partners.

ProSPeCT's mission is to transform cancer care in Australia by establishing a sustainable network for precision genomic testing and clinical trials. This network will enable cancer patients to access the latest therapies with the potential to reduce treatment and testing costs.

The ATGC, which is part of QUT's Centre for Genomic and Personalised Health, has been chosen as an Australian testing site for genomic sequencing coordinated by ProSPeCT. The ATGC is a major contributor of genomic reports to the programme.